Belatacept biosimilar is under clinical development by Alphamab Oncology and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Belatacept biosimilar’s likelihood of approval (LoA) and phase transition for Graft Versus Host Disease (GVHD) took place on 16 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Belatacept biosimilar Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Belatacept biosimilar overview

Belatacept biosimilar is under development for the prevention of autoimmune disorders such as rheumatoid arthritis, lupus nephritis, graft versus host disease and kidney transplant rejection. The drug candidate is a fusion protein which is administered intravenous and subcutaneous. KN-019 acts by targeting CD80 protein. The drug candidate is a biosimilar of belatacept.

Alphamab Oncology overview

Alphamab Oncology (Alphamab) is a clinical-stage biopharmaceutical company.

Quick View Belatacept biosimilar LOA Data

Report Segments
  • Biosimilar
Drug Name
  • Belatacept biosimilar
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Immunology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.